658
Participants
Start Date
June 30, 2001
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Docetaxel
Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
Epirubicin
Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
Epirubicin
Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
Docetaxel
Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
University Hospital of Heraklion, Heraklion
University Hospital of Alexandroupolis Dept. of Medical Oncology, Alexandroupoli
"Agios Savvas Anticancer Hospital of Athens", Athens
"IASO General Hospital of Athens", Athens
"Laikon General Hospital", Athens
"Marika Iliadis Hospital of Athens", Athens
"Metaxa's Anticancer Hospital of Pireas", Athens
401 Military Hospital of Athens, Athens
Air Forces Military Hospital of Athens, Athens
State General Hospital of Larissa, Larissa
"AXEPA General Hospital of Thessaloniki", Thessaloniki
"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER